The compound Salen effectively binds to a number of SARS_CoV_2, the virus that causes COVID-19, proteins. The findings pave the way to developing new therapeutics to fight coronavirus.
Researchers identify the exertion level where aerosol particle emission increases exponentially, offering an explanation as to why exercise intensity may be linked to the transmission of infections.
Researchers have identified elevated levels of a biomarker in the blood that persists for months in long COVID patients who experience neuropsychiatric symptoms.
Anosmia, the loss of the sense of smell which is a common symptom of COVID-19, may be a secondary consequence of immune system inflammation rather than a direct action of the virus.
COVID-19 infection leaves a gene expression signature in the dorsal root ganglia which persist after the virus has cleared. The signature matched other gene expression patterns seen in pain caused by other conditions.
BGE-175, an oral drug that reverses multiple aspects of immune aging effectively prevents death in mouse models of COVID-19.
A newly created stem cell model demonstrates a potential route of entry of the COVID-19 virus, SARS_CoV_2, into the human brain.
Post-mortem studies of COVID-19 patients revealed significant signs of neuroinflammation and impaired brain circuits which researchers believe were caused by the disease. Researchers said the changes noticed in the brains of COVID patients were similar to the changes that occur in both Alzheimer's and Parkinson's disease.
Combining artificial intelligence technology with data sets related to both Alzheimer's and COVID-19, researchers were able to identify a mechanism by which coronavirus can lead to Alzheimer's-like symptoms. The findings add to the growing body of evidence that COVID-19 infection can have lasting effects on brain function.
Two medications commonly used to treat inflammation and HIV infection have been repurposed in the fight against COVID-19. Researchers found combined cepharanthine/nelfinavir therapy can hasten the clearance of coronavirus infection from a person's lungs in as little as 4.9 days. Cepharanthine hindered the entry of SARS_CoV_2 into cells, preventing the virus from binding to a protein on the cell membrane it uses as a gateway. Nelfinavir prevented the virus from replicating inside cells by inhibiting a protein the virus relies on for replication.
SARS_CoV_2, the virus responsible for COVID-19, can directly enter the nervous system. The virus can infect the brain, causing alterations in blood vessels and directly disrupt oxygen supply to the organ.